title: Myasthenia gravis and hepatitis C virus infection.
abstract: Chronic hepatitis C virus (HCV) infections are often associated with extrahepatic immunological manifestations, including various autoimmune disorders. The aims of this study were to determine the prevalence of HCV markers in patients with myasthenia gravis (MG) and to determine any relationship with HCV infection. Eighty-three patients with MG. 40 men aged 20-93 years and 43 women aged 13-87 years (mean age 54 years) were studied. The MG patients were positive for antibody to acetylcholine receptor in addition, their sera was analysed for antibody to HCV (HCVAb) and HCV RNA, HCVAb was detected in two of the 83 patients (2.4%). Four patients were repeatedly HCV RNA positive. They were infected by HCV genotype 1 (one patient), HCV genotype 2a (two patients) and an undetermined HCV genotype in one patient. They received plasmapheresis or intravenous immunoglobulin treatment. Among the four patients, one was infected after the onset of MG without receiving a blood transfusion or using intravenous drugs. The other three had chronic hepatitis C which was discovered at the same time as MG and only one patient had been exposed to blood products. The prevalence of HCV markers in patients with MG (4.8%) was higher than that reported for the general French population, about 1%. This prevalence is similar to that occurring in patients exposed to plasmapheresis or intravenous immunoglobulin. In conclusion, HCV appears to play little, if any, role in causing MG. The higher prevalence of infection among MG patients may be related to transmission in the course of therapy.
authors.affiliation: Laboratoire de Biochimie et Biologie Moléculaire, CHR la Conception, Marseille, France.
authors.forename: P
authors.initials: P
authors.lastname: Halfon
authors.forename: M
authors.initials: M
authors.lastname: Levy
authors.forename: M
authors.initials: M
authors.lastname: San Marco
authors.forename: V
authors.initials: V
authors.lastname: Gerolami
authors.forename: H
authors.initials: H
authors.lastname: Khiri
authors.forename: M
authors.initials: M
authors.lastname: Bourliere
authors.forename: J M
authors.initials: JM
authors.lastname: Feryn
authors.forename: J L
authors.initials: JL
authors.lastname: Gastaut
authors.forename: J
authors.initials: J
authors.lastname: Pouget
authors.forename: G
authors.initials: G
authors.lastname: Cartouzou
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D016174:Hepacivirus / Q000145:classification / Q000235:genetics; D006526:Hepatitis C / Q000150:complications* / Q000453:epidemiology / Q000821:virology; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000150:complications* / Q000453:epidemiology; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies; D013950:Thymus Gland / Q000002:abnormalities
chemical_list: D018937:Hepatitis C Antibodies; D012367:RNA, Viral